What is HC Wainwright’s Forecast for PRAX FY2026 Earnings?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Stock analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of Praxis Precision Medicines in a report issued on Tuesday, November 10th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($13.45) for the year, up from their prior estimate of ($14.09). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($14.03) per share.

A number of other equities analysts also recently issued reports on the company. Raymond James Financial reissued a “strong-buy” rating and set a $945.00 price target on shares of Praxis Precision Medicines in a research report on Monday, August 17th. Wedbush upped their price target on shares of Praxis Precision Medicines from $188.00 to $189.00 and gave the company an “underperform” rating in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Praxis Precision Medicines in a research note on Monday, August 24th. Wall Street Zen downgraded Praxis Precision Medicines from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $575.00 price objective (up from $470.00) on shares of Praxis Precision Medicines in a report on Friday, August 21st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $631.68.

Praxis Precision Medicines Price Performance

Shares of PRAX stock opened at $346.21 on Thursday. The company has a market capitalization of $9.67 billion, a P/E ratio of -27.05 and a beta of 2.85. The company’s 50-day simple moving average is $291.10 and its two-hundred day simple moving average is $314.16. Praxis Precision Medicines has a one year low of $160.11 and a one year high of $392.70.

Praxis Precision Medicines (NASDAQ:PRAX) last announced its quarterly earnings data on Monday, November 9th. The company reported ($3.23) EPS for the quarter, beating the consensus estimate of ($3.54) by $0.31.

Institutional Trading of Praxis Precision Medicines

A number of hedge funds have recently bought and sold shares of PRAX. GW&K Investment Management LLC acquired a new stake in shares of Praxis Precision Medicines in the 3rd quarter worth $61,488,000. Ieq Capital LLC increased its position in shares of Praxis Precision Medicines by 11.5% during the third quarter. Ieq Capital LLC now owns 909 shares of the company’s stock valued at $265,000 after acquiring an additional 94 shares during the last quarter. Voya Investment Management LLC raised its stake in shares of Praxis Precision Medicines by 2.6% in the 3rd quarter. Voya Investment Management LLC now owns 125,359 shares of the company’s stock valued at $36,508,000 after acquiring an additional 3,132 shares during the period. Public Sector Pension Investment Board purchased a new stake in shares of Praxis Precision Medicines in the 3rd quarter valued at approximately $6,990,000. Finally, Royce & Associates LP lifted its holdings in shares of Praxis Precision Medicines by 93.7% in the 3rd quarter. Royce & Associates LP now owns 12,675 shares of the company’s stock worth $3,691,000 after acquiring an additional 6,131 shares during the last quarter. Institutional investors and hedge funds own 67.84% of the company’s stock.

Praxis Precision Medicines News Summary

Here’s some of the latest news about PRAX:

• Positive Sentiment: BTIG and RBC Capital issued “Buy” ratings. RBC also raised its price target to $478 from $462 and maintained an “Outperform” rating, signaling confidence in potential appreciation. BTIG Buy rating RBC Capital Buy rating
• Neutral Sentiment: Praxis presented at the Guggenheim Healthcare Innovation Conference; the provided coverage is a transcript and does not identify a specific new catalyst.
• Negative Sentiment: Wells Fargo cut its price target to $343 from $362 and kept an “Equal Weight” rating. Wedbush raised its target only slightly, to $189 from $188, but retained an “Underperform” rating; both targets are below the share price cited in the reports.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.